Australia - engelsk - APVMA (Australian Pesticides and Veterinary Medicines Authority)

adjuvant technical & marketing services pty ltd - unsulphonatable residue; nc23 paraffinic oil - emulsifiable concentrate - unsulphonatable residue ungrouped active 0.0 u; nc23 paraffinic oil active 812.0 g/l - insecticide

Den europeiske union - latvisk - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - split gripas vīruss, inaktivēts, satur antigēnu: lietots a / vietnam / 1194/2004 (h5n1) līdzīgais celms (nibrg-14) - influenza, human; immunization; disease outbreaks - vakcīnas - aktīvā imunizācija pret a gripas vīrusa h5n1 apakštipa. Šī norāde ir balstīta uz immunogenicity datus no veseliem vecumā no 18 gadiem pēc administrācijas divas devas vakcīnas, kas gatavoti no a/vjetnama/1194/2004 nibrg-14 (h5n1) (skatīt 5. iedaļu. prepandemic gripas vakcīna (h5n1) (split virion, inaktivēta, adjuvanted) glaxosmithkline bioloģiskās izcelsmes zālēm 3. 75 µg būtu jāizmanto saskaņā ar oficiālās vadlīnijas.

Australia - engelsk - APVMA (Australian Pesticides and Veterinary Medicines Authority)

dksh agrisolutions pty ltd - refined canola oil - emulsifiable concentrate - refined canola oil oil-plant extract active 790.0 g/l - adjuvant - adjuvant - improve pesticide deposition | improve rain/fastness | reduce spray drift | improves droplet deposition

Australia - engelsk - APVMA (Australian Pesticides and Veterinary Medicines Authority)

liquid fertiliser pty ltd - canola oil ester - liquid - canola oil ester oil-plant extract active 700.0 g/l - adjuvant - adjuvant | agricultural chemical additive | spray activator | spreading agent | wetting agent - carrier - anti-evaporant | improve rain/fastness | reduce spray drift | adjuvant | evaporant | herbicide application | insecticide application | wetter

Australia - engelsk - APVMA (Australian Pesticides and Veterinary Medicines Authority)

wsd agribusiness pty ltd - ammonium sulfate - aqueous concentrate - ammonium sulfate ammonium active 425.0 g/l - adjuvant - adjuvant | herbicide additive | activator | penetrant | post emergent herbicide | spreading adjuvant | surfactant | wetting agen - tank mixing | additive | agricultural chemical | herbicide | minimise antagonism | spray tank

Israel - engelsk - Ministry of Health

tzamal bio-pharma ltd - gemcitabine as hydrochloride - powder for solution for infusion - gemcitabine as hydrochloride 1500 mg - gemcitabine - gemcitabine - palliative treatment of patients with locally advanced or metastatic non-small cell lung cancer and locallyadvanced or metastatic adenocarcinoma of the pancreas and for patients with 5-fu refractory pancreaticcancer.gemcitabine is indicated for the treatment of patients with bladder cancer at the invasive stage.breast cancer:gemcitabine in combination with paclitaxel is indicated for the treatment of patients with unresectable locallyrecurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy.prior chemotherapy should have included an anthracycline unless clinically contraindicated.ovarian cancer:gemcitabine in combination with carboplatin is indicated for the treatment of patients with recurrent epithelialovarian carcinoma whom have relapsed at least six months after platinum - based therapy.

Den europeiske union - engelsk - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - split influenza virus, inactivated, containing antigen: a/vietnam/1194/2004 (h5n1) like strain used (nibrg-14) - influenza, human - vaccines - prophylaxis of influenza in an officially declared pandemic situation. pandemic influenza vaccine should be used in accordance with official guidance.

Den europeiske union - engelsk - EMA (European Medicines Agency)

novartis vaccines and diagnostics s.r.l. - influenza virus surface antigens (haemagglutinin and neuraminidase) of strain a/viet nam/1194/2004 (h5n1) - influenza, human - vaccines - active immunisation against h5n1 subtype of influenza a virus.; this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain.; prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.

Australia - engelsk - APVMA (Australian Pesticides and Veterinary Medicines Authority)

adjuvant technical & marketing services pty ltd - paraffinic oil - emulsifiable concentrate - paraffinic oil petroleum derivative-oil active 788.0 g/l - insecticide

Israel - engelsk - Ministry of Health

astrazeneca (israel) ltd - olaparib - film coated tablets - olaparib 100 mg - olaparib - ovarian cancer:lynparza is indicated as monotherapy for the: • maintenance treatment of adult patients with advanced (figo stages iii and iv) brca1/2- mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. • maintenance treatment of adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy.first-line maintenance treatment of advanced ovarian cancer in combination with bevacizumablynparza is indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (hrd) positive status defined by either:• a deleterious or suspected deleterious brca mutation, and/or• genomic instability breast cancer:germline brca-mutated her2-negative metastatic breast cancerlynparza is indicated in patients with deleterious or suspected deleterious gbrcam, her2-negative metastatic breast cancer who have been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. patients with hormone receptor (hr)- positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy.adjuvant treatment of germline brca-mutated her2-negative high risk early breast cancer lynparza is indicated for the adjuvant treatment of adult patients with deleterious or suspected deleterious gbrcam human epidermal growth factor receptor 2 (her2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. adenocarcinoma of the pancreas:first-line maintenance treatment of germline brca-mutated metastatic pancreatic adenocarcinomalynparza is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious gbrcam metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen.prostate cancer:• germline or somatic brca1/2 or atm- mutated metastatic castration-resistant prostate cancer lynparza is indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic brca1/2 or atm- mutated metastatic castration-resistant prostate cancer (mcrpc) who have progressed following prior treatment with enzalutamide or abiraterone.• lynparza is indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious hrr-mutated (hrrm) metastatic castration-resistant prostate cancer (mcrpc). select patients for therapy based on an approved companion diagnostic for lynparza